Peptides Information

If GHRP-6 is the peptide people use when they want to eat more, and Ipamorelin is the peptide people use when they want the cleanest possible GH stimulation, then GHRP-2 sits deliberately in the middle — more potent than GHRP-6 for raw GH output, with a more moderate appetite effect, but without reaching the selectivity of Ipamorelin.

For researchers and practitioners who want the strongest GH pulse achievable with a GHRP while keeping the orexigenic (hunger) side effects at a manageable level, GHRP-2 is the logical choice. Its position in the GHRP hierarchy is well-defined, and its research base — which includes diagnostic use in endocrinology — is more clinically grounded than many comparable peptides.

This guide covers everything you need to know about GHRP-2: its mechanism, published research, benefits, dosing protocols, side effects, and where it fits in the broader landscape of growth hormone secretagogues.

⚠️ Important Disclaimer: GHRP-2 is an investigational research peptide. It is not approved by the FDA for human therapeutic use, though it has been used in clinical diagnostic settings in some countries. The information in this article is for educational and research purposes only. Always consult a qualified healthcare professional before using any peptide or hormone-modulating compound.

What Is GHRP-2?

GHRP-2 — also known by its INN (International Nonproprietary Name) Pralmorelin — is a synthetic hexapeptide and ghrelin receptor agonist (GHS-R1a) that stimulates the pituitary gland to secrete growth hormone. Like all GHRPs, it mimics the action of endogenous ghrelin at the receptor level.

GHRP-2 was developed in the 1990s and has been used in Japan and some European countries as a diagnostic agent to test pituitary GH reserve — one of the few GHRPs to have reached formal clinical evaluation. In Japan it has been marketed under the brand name GHRP Kaken 100 for diagnostic use.

Structurally and pharmacologically, GHRP-2 is closely related to GHRP-6 but has been modified to produce a stronger GH release response with a somewhat reduced appetite-stimulating effect. It also produces moderate — rather than GHRP-6-level — elevations in cortisol and prolactin.

How Does GHRP-2 Work?

GHRP-2 binds to the GHS-R1a receptor in the pituitary and hypothalamus, producing two complementary effects:

1. Direct pituitary stimulation: Activating GHS-R1a on somatotroph cells triggers a strong pulse of GH secretion within 15–30 minutes of administration.
2. Somatostatin suppression: Like GHRP-6, GHRP-2 suppresses somatostatin (the GH-inhibiting hormone), which amplifies the net GH response beyond what direct pituitary stimulation alone would produce.

The key pharmacological difference from GHRP-6 is that GHRP-2 appears to have a somewhat higher affinity and efficacy at the GHS-R1a receptor, producing greater GH release per unit dose while the secondary ghrelin effects (appetite, cortisol, prolactin) are comparably lower per unit of GH output. This makes it a more "efficient" GHRP in terms of the ratio of GH release to unwanted side effects — though it does not approach Ipamorelin's selectivity.

Like all secretagogues, GHRP-2 stimulates the body's own pituitary to produce and release GH. The hypothalamic-pituitary feedback axis remains intact throughout use.

GHRP-2 vs. GHRP-6 vs. Ipamorelin: Direct Comparison

Feature	GHRP-2	GHRP-6	Ipamorelin
GH release potency	Very Strong	Strong	Strong
Appetite stimulation	Moderate	High	Minimal
Cortisol increase	Moderate	Moderate	Minimal
Prolactin increase	Moderate	Moderate	Minimal
Clinical diagnostic use	Yes (Japan, some EU countries)	No	No
Best use case	Maximum GH output, moderate appetite	Mass gain, high appetite	Anti-aging, recomposition, clinical

What Does the Research Say?

GHRP-2 (Pralmorelin) has a more substantial clinical research base than most other GHRPs, partially owing to its formal evaluation as a diagnostic agent.

• Arvat et al. (1997) demonstrated in healthy adults that GHRP-2 produced dose-dependent GH release that was significantly greater than GHRP-6 at equivalent doses, with concurrent moderate increases in cortisol and prolactin. The study confirmed GHRP-2's position as one of the most potent injectable GHRPs. (View on PubMed)
• Laferrère et al. (2005) examined the GH response to GHRP-2 in obese versus lean subjects, finding that GH secretion in response to GHRP-2 was significantly blunted in obesity — consistent with the known suppression of GH pulsatility in obese individuals and highlighting the importance of body composition on GH secretagogue response. (View on PubMed)
• GHRP-2's use as a diagnostic provocative test for GH deficiency has been validated in multiple studies, including comparisons with insulin tolerance tests (ITT) and GHRH-arginine tests — the gold standard diagnostic tools for GH deficiency in adults. (View related studies on PubMed)
• Preclinical research has also explored GHRP-2's potential cardioprotective and anti-apoptotic effects — consistent with the broader class effects seen with other GHRPs like GHRP-6 — though human data in these areas is not yet available. (View related studies on PubMed)

Reported Benefits of GHRP-2

1. Strong Growth Hormone Release

GHRP-2 is among the most potent injectable GHRPs for raw GH output. Multiple head-to-head studies confirm it produces greater GH release than GHRP-6 at equivalent doses. When combined with a GHRH analog such as CJC-1295 without DAC, the synergistic GH response is among the strongest achievable with peptide-based secretagogues.

2. Moderate Appetite Stimulation

Unlike GHRP-6's intense hunger effect, GHRP-2's appetite stimulation is moderate and more manageable for most users. This makes it a practical middle ground for individuals who want strong GH stimulation without the overwhelming orexigenic effect of GHRP-6, but who don't need the near-zero hunger profile of Ipamorelin.

3. Lean Muscle Mass and Body Composition

Elevated GH and IGF-1 from GHRP-2 use support protein synthesis, muscle fiber repair, and lean mass accumulation. The moderate appetite increase can support a caloric surplus for muscle-building phases without the extreme hunger management challenges of GHRP-6.

4. Improved Sleep and Recovery

GHRP-2 amplifies the nocturnal GH pulse when administered before bed, deepening slow-wave sleep and improving the restorative quality of sleep. Recovery from training and physical stress is enhanced through both the direct sleep effect and the downstream GH and IGF-1 elevation.

5. Fat Loss Through Lipolysis

Elevated GH drives lipolysis — the mobilization of stored fatty acids for energy. For individuals who can manage the moderate appetite increase, GHRP-2's strong GH output makes it effective in fat-loss phases, particularly when combined with a GHRH analog and appropriate dietary control.

6. Skin, Collagen, and Joint Health

As with other GH secretagogues, GH and IGF-1 elevation through GHRP-2 supports collagen synthesis, improving skin elasticity, connective tissue repair, and joint health over sustained protocols.

7. Diagnostic Application for GH Deficiency

In formal clinical endocrinology, GHRP-2 (Pralmorelin) has been used as a provocative test agent to assess pituitary GH reserve. A blunted GH response to GHRP-2 administration is used as a diagnostic indicator of GH deficiency — a clinical application that no other GHRP in this series has achieved.

GHRP-2 Dosage and Protocol

The following reflects commonly discussed research protocols. This is not medical advice.

• Typical dose: 100–300 mcg per injection
• Injection route: Subcutaneous (sub-Q), typically into abdominal fat
• Frequency: 2–3 times daily
• Best timing: Fasted state — at least 30–60 minutes before eating or 2–3 hours after a meal. Before bed, first thing in the morning, and/or pre-workout are the most common injection windows.
• Cycle length: 3–6 months followed by a break of 4–8 weeks

Common Stack Protocols with GHRP-2

Stack	Doses	Goal
GHRP-2 + CJC-1295 w/o DAC	100–200 mcg each, 2–3x/day	Maximum GH output for muscle growth and recovery
GHRP-2 + Sermorelin	100–200 mcg each, 1–2x/day	Clinically accessible GH optimization with strong GH pulse
GHRP-2 alone	100–300 mcg, 2–3x/day	Standalone GH stimulation; effective but less synergistic

Note on GHRP-2 vs. Ipamorelin in stacks: When maximum GH output is the priority and the user can tolerate moderate cortisol and prolactin elevation, GHRP-2 is often preferred over Ipamorelin as the GHRP component of a stack. When tolerability and side effect minimization are the priority, Ipamorelin remains the superior choice.

Side Effects and Safety Considerations

Common Side Effects

• Increased hunger — moderate, typically peaking 30–60 minutes after injection. Less intense than GHRP-6 but more noticeable than Ipamorelin.
• Cortisol elevation — transient and moderate. Most relevant for individuals already dealing with high-stress situations, elevated baseline cortisol, or those using cortisol-sensitive protocols.
• Prolactin elevation — mild to moderate. Monitor for gynecomastia symptoms with extended use.
• Water retention — fluid retention in the extremities, linked to GH-driven fluid shifts. Usually manageable and resolves with dose reduction or discontinuation.
• Flushing, warmth, or tingling shortly after injection.
• Headache, particularly in the initial days of use or at doses above 200 mcg.
• Injection site redness or irritation.

Important Safety Considerations

• Active malignancy: Contraindicated. GH and IGF-1 elevation may promote tumor cell growth.
• Cortisol-sensitive individuals: Those with adrenal fatigue, chronic stress, or in therapeutic contexts where cortisol management is important should consider Ipamorelin instead.
• Prolactin monitoring: If prolactin-related symptoms develop (gynecomastia, sexual dysfunction, mood changes), check serum prolactin and consider switching to Ipamorelin.
• Glucose and insulin sensitivity: Monitor fasting glucose in extended protocols, as with all GH-stimulating compounds.
• Obesity and blunted GH response: Research shows that GH secretagogue response is significantly reduced in individuals with obesity. Higher body fat levels are associated with attenuated GH release from all secretagogues including GHRP-2.

Recommended labs: IGF-1, fasting glucose, cortisol (morning), prolactin, and a full hormone panel before and at regular intervals during extended GHRP-2 use.

How to Reconstitute GHRP-2

GHRP-2 is supplied as a lyophilized (freeze-dried) powder, typically in 5 mg vials, and must be reconstituted with bacteriostatic water before use.

1. Use bacteriostatic water (sterile water with 0.9% benzyl alcohol) for reconstitution and preservation.
2. Inject bacteriostatic water slowly into the vial, letting it run down the inside wall — do not inject directly onto the powder.
3. Gently swirl until fully dissolved. Do not shake.
4. Store the reconstituted vial in the refrigerator (2–8°C). Do not freeze after reconstitution.
5. Reconstituted GHRP-2 is typically stable for 4–6 weeks under refrigeration.

Who Uses GHRP-2?

• Athletes and bodybuilders seeking maximum GH output from a GHRP, who find GHRP-6's hunger unmanageable but want stronger GH stimulation than Ipamorelin provides
• Researchers focused on body composition — lean mass gain combined with fat loss — using GHRP-2 as the GHRP component of a GHRH+GHRP stack
• Clinical endocrinology — in countries where Pralmorelin is approved as a diagnostic agent for GH deficiency testing
• Advanced users who have previously used Ipamorelin and are seeking to step up GH output for a more intensive phase of their protocol

Frequently Asked Questions About GHRP-2

Is GHRP-2 stronger than GHRP-6?

Yes. Multiple comparative studies confirm that GHRP-2 produces greater GH release than GHRP-6 at equivalent doses. The trade-off is that GHRP-2 comes with moderate cortisol and prolactin elevation — similar to GHRP-6 — while having a somewhat lower appetite-stimulating effect.

Is GHRP-2 better than Ipamorelin?

It depends entirely on the goal. GHRP-2 produces a stronger GH pulse than Ipamorelin at comparable doses. However, Ipamorelin produces its GH stimulation with minimal cortisol, prolactin, and hunger effects. For anti-aging, recovery, and body recomposition protocols where side effect minimization is important, Ipamorelin is the superior choice. For maximum GH output where moderate side effects are acceptable, GHRP-2 is preferred.

What is Pralmorelin?

Pralmorelin is the International Nonproprietary Name (INN) for GHRP-2. It is the same compound — the different name reflects its clinical designation as opposed to its research chemical name. In Japan and some other countries, Pralmorelin is used as a diagnostic tool to evaluate pituitary GH secretory capacity.

Does GHRP-2 cause water retention?

Yes, GH-induced fluid retention is a common effect with GHRP-2, as with all GH secretagogues. The degree of water retention is related to dose and to the magnitude of IGF-1 elevation. Starting at lower doses (100 mcg) and titrating up helps assess individual sensitivity. Reducing dose or temporarily discontinuing use resolves the retention.

Can GHRP-2 be used for fat loss?

Yes, and more effectively than GHRP-6 for most fat-loss contexts because the appetite stimulation is more moderate. GHRP-2's strong GH output drives significant lipolysis. When stacked with CJC-1295 without DAC in a hypocaloric protocol, it can be an effective fat-loss tool — provided the user can manage the moderate hunger increase.

Does GHRP-2 require post-cycle therapy (PCT)?

No. GHRP-2 does not affect the hypothalamic-pituitary-gonadal (HPG) axis, testosterone, LH, or FSH. It operates exclusively through the GH axis. Post-cycle therapy is neither required nor relevant after GHRP-2 use.

Can GHRP-2 and GHRP-6 be stacked together?

There is no meaningful rationale for stacking two GHRPs — both work on the same receptor (GHS-R1a) and their effects are not additive in the way that a GHRP+GHRH combination is. Stacking GHRP-2 with GHRP-6 would primarily compound the cortisol, prolactin, and appetite effects without proportionally increasing GH output. The correct pairing is always a GHRP with a GHRH analog.

Where to Learn More

• GHRP-2 / Pralmorelin research on PubMed
• Growth hormone releasing peptide-2 studies on PubMed
• The Endocrine Society
• Growth Hormone Research Society

For research-based guides on every major growth hormone releasing peptide — from GHRPs and GHRH analogs to oral secretagogues, recovery peptides, and metabolic compounds — visit our complete resource library.

Final Thoughts

GHRP-2 occupies a well-defined niche in the GHRP hierarchy: the highest GH output in its class, with a side effect profile that sits between GHRP-6 and Ipamorelin. For researchers and practitioners who have outgrown Ipamorelin's output ceiling but find GHRP-6's hunger effect unworkable, GHRP-2 is the natural next step.

Its clinical validation as a diagnostic agent in formal endocrinology — under the name Pralmorelin — also gives it a degree of scientific credibility that few other research GHRPs can claim. That history doesn't eliminate the need for careful use and monitoring, but it does provide a more solid evidence base for understanding its effects and safety profile.

The next post in this series covers Hexarelin — the most potent GHRP in the entire class, with the strongest GH release and the most significant desensitization risk. Stay tuned.